AP01
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Pulmonary Fibrosis
Conditions
Progressive Pulmonary Fibrosis
Trial Timeline
Apr 3, 2024 → Jun 1, 2027
NCT ID
NCT06329401About AP01
AP01 is a phase 2 stage product being developed by Avalyn Pharmaceuticals for Progressive Pulmonary Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06329401. Target conditions include Progressive Pulmonary Fibrosis.
What happened to similar drugs?
2 of 20 similar drugs in Progressive Pulmonary Fibrosis were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06329401 | Phase 2 | Recruiting |
Competing Products
20 competing products in Progressive Pulmonary Fibrosis